Sikkerhedsprofilen for Ratiograstim i disse kliniske forsøg svarede til profilen for det referenceprodukt, der blev anvendt i forsøgene.
The safety profile of Ratiograstim observed in these clinical studies was consistent with that reported with the reference product used in these studies.